PE20150226A1 - Agentes terapeuticos para administracion subcutanea optimizados - Google Patents

Agentes terapeuticos para administracion subcutanea optimizados

Info

Publication number
PE20150226A1
PE20150226A1 PE2014001639A PE2014001639A PE20150226A1 PE 20150226 A1 PE20150226 A1 PE 20150226A1 PE 2014001639 A PE2014001639 A PE 2014001639A PE 2014001639 A PE2014001639 A PE 2014001639A PE 20150226 A1 PE20150226 A1 PE 20150226A1
Authority
PE
Peru
Prior art keywords
therapeutic agents
subcutaneous administration
optimized therapeutic
cpaverage
cmax
Prior art date
Application number
PE2014001639A
Other languages
English (en)
Spanish (es)
Inventor
William Henry
Richard Wolf-Garraway
John Charles Mayo
Michael James Earl
Original Assignee
Cantab Biopharmaceuticals Patent Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by Cantab Biopharmaceuticals Patent Ltd filed Critical Cantab Biopharmaceuticals Patent Ltd
Publication of PE20150226A1 publication Critical patent/PE20150226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2014001639A 2012-04-16 2013-04-16 Agentes terapeuticos para administracion subcutanea optimizados PE20150226A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents

Publications (1)

Publication Number Publication Date
PE20150226A1 true PE20150226A1 (es) 2015-02-14

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001639A PE20150226A1 (es) 2012-04-16 2013-04-16 Agentes terapeuticos para administracion subcutanea optimizados

Country Status (29)

Country Link
US (2) US20150086524A1 (forum.php)
EP (1) EP2838566A2 (forum.php)
JP (3) JP2015512927A (forum.php)
KR (1) KR102137290B1 (forum.php)
CN (1) CN104411335A (forum.php)
AP (1) AP2014008049A0 (forum.php)
AU (3) AU2013248296A1 (forum.php)
BR (1) BR112014025737A2 (forum.php)
CA (1) CA2869993C (forum.php)
CL (1) CL2014002773A1 (forum.php)
CO (1) CO7151496A2 (forum.php)
CR (1) CR20140475A (forum.php)
EA (1) EA033469B1 (forum.php)
EC (1) ECSP14023048A (forum.php)
GB (3) GB201910190D0 (forum.php)
GE (1) GEP201706716B (forum.php)
HK (1) HK1200695A1 (forum.php)
IL (1) IL235129B (forum.php)
IN (1) IN2014DN08598A (forum.php)
MD (1) MD20140123A2 (forum.php)
MX (2) MX2014012512A (forum.php)
MY (1) MY190257A (forum.php)
NI (1) NI201400122A (forum.php)
NZ (1) NZ701205A (forum.php)
PE (1) PE20150226A1 (forum.php)
PH (1) PH12014502314B1 (forum.php)
SG (1) SG11201406492YA (forum.php)
WO (1) WO2013156488A2 (forum.php)
ZA (1) ZA201407370B (forum.php)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498815B (zh) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 重组人激肽释放酶的化学修饰物及其应用
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP3307237A1 (en) * 2015-06-12 2018-04-18 Laboratoire Français du Fractionnement et des Biotechnologies Injectable composition of factor vii and fillers
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
WO2021216372A1 (en) * 2020-04-23 2021-10-28 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (forum.php) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
EP0662078B1 (en) 1992-09-28 2003-05-02 Research Corporation Technologies, Inc. Reagents for peptide couplings
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
JPH08325270A (ja) * 1995-05-31 1996-12-10 Bristol Myers Squibb Co β−ラクタマーゼに対するポリマープロドラッグおよびその使用
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
NZ521257A (en) * 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
EP1280548B1 (en) 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor VII
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
ES2363205T3 (es) * 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
EP2338523B1 (en) * 2003-02-26 2024-01-17 Nektar Therapeutics Polymer-factor viii moiety conjugates
SI1620118T1 (sl) * 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US7612066B2 (en) 2004-03-04 2009-11-03 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
EP1765411B2 (en) * 2004-06-30 2017-10-11 Nektar Therapeutics Polymer-factor ix moiety conjugates
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
WO2008081024A1 (en) 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
SG174077A1 (en) 2007-04-13 2011-09-29 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
WO2009047500A1 (en) 2007-10-09 2009-04-16 Polytherics Limited Novel conjugated proteins and peptides
WO2009052323A2 (en) 2007-10-16 2009-04-23 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulationfactor viia modulator
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
WO2009140015A2 (en) * 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
RU2496521C2 (ru) * 2008-04-24 2013-10-27 Кантаб Байофармасьютикалз Патентс Лимитед Конъюгаты фактора ix с увеличенным временем полужизни
US20110112029A1 (en) * 2008-05-23 2011-05-12 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
WO2010045321A2 (en) * 2008-10-15 2010-04-22 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
LT2349342T (lt) * 2008-10-17 2018-10-10 Baxalta GmbH Modifikuoti kraujo faktoriai, apimantys nedidelį vandenyje tirpaus polimero kiekį
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
CN102497884A (zh) * 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
KR102229967B1 (ko) * 2010-07-30 2021-03-19 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
EP2838566A2 (en) 2015-02-25
AP2014008049A0 (en) 2014-11-30
JP2018024684A (ja) 2018-02-15
WO2013156488A3 (en) 2014-01-16
CL2014002773A1 (es) 2015-01-16
PH12014502314A1 (en) 2015-01-12
BR112014025737A2 (pt) 2017-07-04
CA2869993C (en) 2023-05-23
HK1200695A1 (en) 2015-08-14
JP2015512927A (ja) 2015-04-30
US11351112B2 (en) 2022-06-07
MD20140123A2 (ro) 2015-04-30
ECSP14023048A (es) 2015-11-30
PH12014502314B1 (en) 2020-01-31
CA2869993A1 (en) 2013-10-24
IL235129A0 (en) 2014-12-31
CO7151496A2 (es) 2014-12-29
AU2018200111B2 (en) 2019-11-07
MY190257A (en) 2022-04-11
NZ701205A (en) 2016-02-26
CR20140475A (es) 2015-01-23
WO2013156488A2 (en) 2013-10-24
AU2018200111A1 (en) 2018-01-25
KR20140146171A (ko) 2014-12-24
GB201910190D0 (en) 2019-08-28
GB201910184D0 (en) 2019-08-28
CN104411335A (zh) 2015-03-11
US20150086524A1 (en) 2015-03-26
AU2013248296A1 (en) 2014-11-13
AU2020200842A1 (en) 2020-02-27
IL235129B (en) 2022-06-01
ZA201407370B (en) 2017-09-27
JP2019131593A (ja) 2019-08-08
GEP201706716B (en) 2017-08-10
EA033469B1 (ru) 2019-10-31
EA201491702A1 (ru) 2015-03-31
SG11201406492YA (en) 2014-11-27
MX2014012512A (es) 2015-01-15
JP6550107B2 (ja) 2019-07-24
GB201418864D0 (en) 2014-12-03
MX2020014208A (es) 2021-03-09
US20180036229A1 (en) 2018-02-08
GB2516388A (en) 2015-01-21
IN2014DN08598A (forum.php) 2015-05-22
NI201400122A (es) 2016-12-02
KR102137290B1 (ko) 2020-07-23

Similar Documents

Publication Publication Date Title
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
EA201691193A1 (ru) Система доставки лекарственных средств
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
NZ628398A (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
MX2015008685A (es) Tratamiento de artritis psoriasica usando apremilast.
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
CO7190239A2 (es) Dialisato a base de polímero
EP4360621A3 (en) Formulations of bendamustine
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
AR088267A1 (es) Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos
MX362804B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla
MX2016014307A (es) Administración asistida de agentes de tratamiento de plantas.
BR112013001462B8 (pt) Composições
EA202091743A1 (ru) Вакцинация дендритными клетками параллельно с химиотерапией
MX383557B (es) Formulaciones inyectables de paracetamol.
AR105503A1 (es) Concentrado que contiene alprostadil

Legal Events

Date Code Title Description
FG Grant, registration